Background/aim: Advanced renal cell carcinoma (RCC) is commonly treated with immune checkpoint inhibitor (ICI)-based therapies. However, patient responses vary, and predictive biomarkers remain limited. Here, we demonstrate that ... ...

请注册登录后继续浏览